Share Name Share Symbol Market Type Share ISIN Share Description
Animalcare Group Plc LSE:ANCR London Ordinary Share GB0032350695 ORD 20P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 275.00 270.00 280.00 275.00 275.00 275.00 15,544 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 74.0 0.9 -0.1 - 165

Animalcare Share Discussion Threads

Showing 151 to 168 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
From WealthOracleAM.... Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently. Other than the “underappreciated” by investors investment in 2017, the Group has been performing rather well. They have reduced their debt and increasing the cash generated from operations, thus gearing is minuscule at 16%. Revenue is growing at 39.1% CAGR, ROCE at 4.52% and dividends were doubled in 2020 from 2019, so there is plenty of return for the investors. However, ANCR remains very highly priced, with P/S just below the industry average and EV/EBITDA being quite high at 25.09.
It is 23% of the company and the placing price is where the share price was 6 weeks ago so the discount is not that surprising. It’s clear that Cardon has been wanting to move onto other things since he gave up being CEO in 2018 and then moved to non exec in 2019. At least the overhang is gone now.
Secondary placing - Hit share price very hard. Views? 8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021
Nice uplift since I bought during the first week of May. Our vet uses ANCR products:when i mentioned the imminent release of a new product, the vet was very interested . Suppliers of products to vets are onto a good thing.
that video now on ggp share board , a good example for other shares
The growth in pet ownership over lockdown and owner’s desires to keep their pets fit and healthy has been great news for the pet care sector. However, who are going to be the long-term winners from the current pet boom? Investor’s Champion’s research highlights some terrific companies which should continue to do well, including a star performer. #ancr #chwy #cvsg #elan #idxx #nesn #pets #zts
The website identibase is in complete disarray at present, shambolic. Vets, animal charities and private individuals unable to register chips they have paid for.Fraudulent incompetence over the last few weeks
The latest interim results suggest that the efforts of newish CEO Jenny Winter appearing to be bearing fruit, despite the short term disruptions. Revenue declined 4.4% to £34.5m due to the impact of the pandemic, with largest product category of Companion Animals seeing a 10.6% decline to £21.2m and Production animals seeing 13.1% growth to £10.5m. Equine and other declined 10% to £2.7m. More on the Investor's Champion website.
The full statement from the auditor's report - Hedging opinion (imo) Material uncertainty related to going concern – Group and Parent Company In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 3 to the group financial statements and note 1 to the parent company’s financial statements concerning the group’s and parent company’s ability to continue as a going concern. The Group’s forecast cash flows contain assumptions over revenue, profitability and cash generation. These forecasts have been stress-tested for severe but plausible scenarios that could impact the Group. These show that in a more prolonged severe downturn there may be a potential breach of the leverage covenant for the Group’s borrowing facility. If such a breach were to occur the Group would need to obtain a covenant relaxation or waiver from the Group’s banking syndicate. This condition, along with the other matters explained in note 3 to the financial statements, indicates the existence of a material uncertainty which may cast significant doubt about the group’s and parent company’s ability to continue as a going concern. The financial statements do not include the adjustments that would result if the group and parent company were unable to continue as a going concern. Explanation of material uncertainty Management and the Board considered the potential impact of COVID-19 on the current and future operations of the business. In doing so, management focused on the Group’s ability to continue as a going concern by performing a detailed bottom-up analysis of the impact of COVID-19 on revenue, EBITDA and cashflows. Management made estimates and judgements that are critical to the outcome of these considerations. Three scenarios were modelled – a new base case and two further downside scenarios. This analysis has been used in conjunction with an assessment of the Group’s liquidity and consideration of loan covenants. Audit procedures performed In assessing management’s consideration of the potential impact of COVID-19, we undertook the following procedures: • We obtained management’s board report that details the Group’s assessment and conclusions with respect to their ability to continue as a going concern; • We assessed the initial 2020 (preCOVID-19) budget as well as the new base case forecast and two further downside scenarios (each of which factor in COVID-19 overlays); • We confirmed that the initial 2020 (pre COVID-19) budget was board approved. In addition, we evaluated the historical accuracy of the budgeting process to assess the reliability of the data; • In relation to the COVID-19 overlays, we held discussions with management to understand and challenge the rationale behind the assumptions made, using our knowledge of the business and industry; • We reviewed the latest trading results for the year to date in 2020 and compared to management’s original budget, FY19 actuals and revised forecasts, and considered the impact of these actual results on the future forecast period; • We understood the mitigating actions taken by management, including suspending the final dividend payment; • We reviewed management’s sensitivity scenarios and we challenged management to run further downside scenarios in order to assess the possible impact of headroom against their borrowing facilities; and • We reviewed the disclosures included within the Annual Report and consider these to be appropriate.
Hello Everyone,Not sure if you have seen this, re Animalcare."Animalcare Group plc Auditor Raises 'Going Concern' DoubtAnimalcare Group plc filed its Annual on Jun 09, 2020 for the period ending Dec 31, 2019. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern."CheersMartin
Tipped by Chris Boxall of FAM today.
Perking up on some chunky volume
value viper
i remember this one - i was looking at it pre-merger and never really understood why the management went for it. Guess I will look in after the results at the end of the month but the text from the statements doesn't fit with the figures. Having worked in a bank turnaround story for 10 years - I've seen many new CEOs come in and kitchen sink the first set of results and we'll have to see if Jenny Winter does the same.
that is one nasty looking chart
time this one started to lose the "dog status" if you know what i mean - welcoming all new posters for comments - good luck all
value viper
i have set up a new thread that may (?) help the price (?) if nothing else ; this one is 11 years old - welcome to see posters over there - see if this dog can start to turn
value viper
New CEO in Jenny Winter recently appointed has an opportunity to finally put this business back on track. Hideous journey to date with frankly pure value destruction further to the Ecuphar merger. An AIM 2017 transaction award for this deal leaves somewhat of a nasty taste in the mouth - the chart says it all. However, profitable and growth markets with a renewed focus on higher margins part of strategy. Results at the end of April will hopefully show that green shoots are visible. One to watch in my view. DYOR and good luck to all investors new and existing.
value viper
2019 AGM 25/06/2019 2018 Year End Preliminary Announcement 30/04/2019
Chat Pages: 7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220627 12:41:33